7 completed, 1 active not recruiting, 1 withdrawn. 9 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Active not recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 2 |
Follow icatibant: new trials by email Literature Review of icatibant trials Research Report on icatibant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhibition of Bradykinin in COVID-19 Infection With Icatibant Icatibant, 0.9% Sodium Chloride Injection - SARS CoV 2 Infection | Phase 2 / Phase 3 | Completed | Belfast Health and Social Care Trust | 32 | 2022-05-16 | 2023-09-07 |
| Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection Firazyr, SoC - COVID-19 Pneumonia | Phase 2 | Completed | Sebastian Videla | 73 | 2021-04-12 | 2022-08-03 |
| Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study). C1 Inhibitor Human, Icatibant Injection, Placebo - Covid19 | Phase 2 | Completed | GCS Ramsay Santé pour l'Enseignement et la Recherche | 44 | 2021-02-04 | 2022-12-22 |
| I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients Remdesivir, Imatinib Mesylate, Dexamethasone - COVID-19 | Phase 2 | Active not recruiting | QuantumLeap Healthcare Collaborative | 1500 | 2020-07-31 | 2026-03-16 |
| Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2 Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid - Heart Failure NYHA Class I, Heart Failure NYHA Class II | Phase 2 | Withdrawn | Vanderbilt University Medical Center | 2017-09-01 | 2018-01-11 | |
| Mitochondria and Chronic Kidney Disease Icatibant, Placebo - Hemodialysis-Induced Symptom, Mitochondrial Diseases | Phase 2 | Completed | Vanderbilt University Medical Center | 11 | 2017-08-01 | 2019-10-29 |
| Bradykinin Receptor Antagonism During Cardiopulmonary Bypass HOE 140, Aminocaproic Acid, Placebo - Cardiopulmonary Bypass, Inflammation | Phase 2 / Phase 3 | Completed | Vanderbilt University | 150 | 2006-05-01 | 2013-11-25 |
| Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis HOE140 Icatibant - Joint Disease | Phase 2 | Completed | Sanofi | 590 | 2006-02-01 | 2012-02-17 |
| AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study Icatibant (subcutaneous) and plazebo (intravenous), Cortisone + Clemastin (intravenous) and plazebo (subcutaneous) - Angioedema | Phase 2 | Completed | Technical University of Munich | 2011-12-23 |
COVID-19 (3) · Angioedema (1) · Disease (1) · Inflammation (1) · Joint Diseases (1) · Mitochondrial Diseases (1) · Osteoarthritis (1) · Respiratory Distress Syndrome (1) · Respiratory Insufficiency (1)
Vanderbilt University Medical Center (2) · Belfast Health and Social Care Trust (1) · GCS Ramsay Santé pour l'Enseignement et la Recherche (1) · QuantumLeap Healthcare Collaborative (1) · Sanofi (1) · Sebastian Videla (1) · Technical University of Munich (1) · Vanderbilt University (1)
United States (5) · Germany (2) · Austria (1) · Czechia (1) · France (1) · Poland (1) · Spain (1) · United Kingdom (1)
Derek W Russell, MD (1) · Joe Kidney, MD (1) · Kathleen D Liu, MD (1) · Laura Esserman, MD (1) · Mias Pretorius, MBChB (1) · Murat Bas, Dr. (1)
PMID 23361105, PMID 25629740, PMID 34473343, PMID 35413921, PMID 36610464, PMID 36883141, PMID 38035747, PMID 39592213, PMID 40462830, PMID 42799508